Teva to resume making pediatric cancer drug after shortage caused ‘a nightmare’

(By Maia Anderson for Becker’s Hospital Review)

Teva Pharmaceuticals will resume producing the vital cancer drug vincristine after a shortage caused a “nightmare situation” for physicians and patients, according to STAT.

Vincristine is used to treat several childhood cancers, including leukemias, lymphomas and brain tumors.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.